phrykt

AEON Biopharma, Inc. (AEON): who owns it and who trades it

As of Nov 16, 2026, AEON insiders reported 1 purchase worth $242K in the last 12 months. The largest buyer was Timothy P Lynch (10% owner), with $242K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling AEON Biopharma

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, AEON insiders reported $242K of open-market purchases and $0 of sales.

Purchases, 12 months
$242K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 19, 2026
Filed Aug 21, 2026

Purchases and sales by month

$242K$242KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 19, 2026Timothy P Lynch10% ownerPurchase1.15M$0.21$242KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Timothy P Lynch10% owner$242K–Aug 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AEON short interest

Moderate short interest. 5.3% of AEON shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 1048%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.66M AEON shares were sold short, 5.3% of the shares outstanding, down 18.1% from the report before. At the average daily volume of 415,775 shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

5.34%May 15Oct 307.40%

Days to cover

6.4May 15Oct 307.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.66M5.34%-18%415,7756.4
Oct 15, 20263.25M6.52%+50%2.13M1.5
Sep 30, 20262.17M4.35%-26%11.39M1.0
Sep 15, 20262.95M5.91%+63%24.52M1.0
Aug 31, 20261.81M3.63%+61%7.39M1.0
Aug 14, 20261.13M2.26%+28%343,6153.3
Jul 31, 2026876,9673.47%-21%993,4011.0
Jul 15, 20261.11M4.40%+594%6.55M1.0
Jun 30, 2026160,2690.63%-10%28,9865.5
Jun 15, 2026177,8950.70%-19%32,9805.4
May 29, 2026219,2200.87%-5%72,5923.0
May 15, 2026231,8880.92%+48%69,6493.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

AEON Biopharma company events

AEON Biopharma filed 17 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 3, 2026.

  1. Nov 3, 2026AgreementAEON Biopharma, Inc. entered into an Amendment to Two-Year Milestone Warrant to Purchase Common Stock or Pre-Funded Warrants with holders representing at least 67% of the shares of Common Stock and Pre-Funded Warrants issuable under the Company’s outstanding two-year milestone warrants issued on… Filing
  2. Oct 23, 2026AnnouncementShared information with investors. Filing
  3. Sep 30, 2026AnnouncementThe Company announced receipt of the official minutes from its BPD Type 2b meeting with the FDA regarding ABP-450’s development pathway as a proposed biosimilar to BOTOX ® (onabotulinumtoxinA). Filing
  4. Aug 12, 2026ResultsReleased financial results. Filing
  5. Aug 3, 2026AnnouncementThe Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of NYSE American. Filing
  6. Jul 23, 2026AnnouncementAs previously reported, on July 15, 2026, AEON Biopharma, Inc. completed a public offering, pursuant to an underwriting agreement with Lake Street Capital Markets, LLC, as representative of the several underwriters named therein. Filing
  7. Jul 15, 2026AgreementAEON Biopharma, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, as representative of the several underwriters named therein, relating to the Company's underwritten public offering of (i) 17,851,599 shares of the Company's Class A common stock, par value $0.0001… Filing
  8. Jun 17, 2026VoteReported shareholder vote results. Filing
  9. May 14, 2026AnnouncementShared information with investors. Filing
  10. May 14, 2026ResultsReleased financial results. Filing
  11. Apr 3, 2026ListingAEON Biopharma, Inc. received an additional written notice of non-compliance from NYSE American LLC indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide. Filing
  12. Mar 30, 2026ResultsReleased financial results. Filing
  13. Mar 9, 2026LeadershipThe Board of Directors of AEON Biopharma, Inc. appointed John Bencich, age 49, as the Company’s Chief Financial Officer, effective as of March 9, 2026 and principal financial officer, effective as of April 1, 2026. Filing
  14. Jan 21, 2026LeadershipThe Company held its Special Meeting of Stockholders on January 21, 2026 as described in the Company’s proxy statement for the Special Meeting, filed with the SEC on December 29, 2025. Filing
  15. Jan 12, 2026AnnouncementShared information with investors. Filing
  16. Dec 15, 2025AgreementExchange Agreement As previously disclosed, on March 19, 2024, AEON Biopharma Inc., a Delaware corporation entered into a subscription agreement with Daewoong Pharmaceuticals, Co., LTD relating to the Company’s sale and issuance of senior secured convertible notes in the principal amount of up to… Filing
  17. Dec 4, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

AEON Biopharma financials

Famous investors that hold AEON

1 of the 50 well-known investors we track reported holding AEON in their latest 13F filing. The largest position is Ken Griffin's, worth $16.7K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202655,684$16.7K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named AEON in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Ikarian Capital, LLC13G9.9%
Nov 16, 2026Ikarian Capital, LLC13G9.9%
Nov 13, 2026Nantahala Capital Management, LLC13G10.0%
Nov 13, 2026Nantahala Capital Management, LLC13G10.0%
Nov 10, 2026Daewoong Co., Ltd.13D/A30.6%
Nov 10, 2026Daewoong Co., Ltd.13D/A30.6%

Questions about AEON Biopharma, Inc. (AEON) stock

Are AEON insiders buying or selling?

In the last 12 months, AEON insiders reported 1 open-market purchase worth $242K and no sales. The latest trade was on Aug 19, 2026. See every trade.

What is the short interest in AEON?

As of Oct 30, 2026, 2.66M AEON shares were sold short, 5.3% of the shares outstanding, down 18.1% from the report before. At the average daily volume of 415,775 shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold AEON?

1 of the 50 well-known investors we track reported AEON in their latest 13F filing, including Ken Griffin. The largest position is worth $16.7K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.